Incyte has revealed promising early clinical data for its potential first-in-class CDK2 inhibitor, INCB123667, in patients with advanced solid tumours. The data, presented at the European…
Discover precise insights into the intersections of health, society, and culture in the UK at Social Equality. Your reliable source for clear and comprehensive coverage.